BBOT Q3 2025 Earnings — BridgeBio Oncology Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BBOTBridgeBio Oncology Therapeutics Inc.

$820M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$49M

Net Income

-$45M

EPS (Diluted)

$-1.90

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$71M

Free Cash Flow

-$71M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$485M

Total Liabilities

$38M

Stockholders' Equity

$447M

Cash & Equivalents

$409M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$49M	-$20M	-150.1%
Net Income	-$45M	-$17M	-158.4%